K. Starkey

Progress in our understanding of the pathogenesis of Graves ophthalmopathy

M. Ludgate, K. Starkey, 2000 .

Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?

M. Evans, W. Joba, A. Heufelder, 2003, The Journal of clinical endocrinology and metabolism.

Biological activity of activating thyroid-stimulating hormone receptor mutants depends on the cellular context.

R. Paschke, D. Wynford‐Thomas, D. Fuhrer, 2003, Endocrinology.

Impact of High Ratios of Plasma–to–Red Cell Concentrate on the Incidence of Acute Respiratory Distress Syndrome in UK Transfused Combat Casualties

M. Midwinter, H. Doughty, J. Morrison, 2013, Shock.

Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo.

M. Ludgate, N. Jordan, G. Jones, 2003, Journal of molecular endocrinology.

In the thick of it: cerebral venous sinus thrombosis precipitated by iron-deficiency anaemia and sickle cell trait

A. M. Johnston, I. Boon, K. Starkey, 2016, BMJ Case Reports.

Adipogenesis in thyroid eye disease.

M. Crisp, M. Ludgate, C. Lane, 2000, Investigative ophthalmology & visual science.